| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
110,820,000 |
| Market
Cap: |
476.53(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.81 - $10.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 7.5 |
| Insider 3/6 Months : 8.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Precision Biosciences is a clinical stage gene editing company focused on improving life by developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its wholly owned proprietary ARCUS genome editing platform. Co. is simultaneously conducting a Phase 1/2a clinical trial evaluating PBCAR0191 as a potential first-in-class and a Phase 1 clinical trial evaluating PBCAR19B as, if approved, a potential CD19-targeting CAR T cell therapies in adult patients with relapsed or refractory, B-cell malignancies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,217 |
25,666 |
115,666 |
| Total Buy Value |
$0 |
$63,268 |
$128,390 |
$171,590 |
| Total People Bought |
0 |
3 |
4 |
4 |
| Total Buy Transactions |
0 |
4 |
8 |
9 |
| Total Shares Sold |
0 |
57,443 |
61,043 |
412,917 |
| Total Sell Value |
$0 |
$271,525 |
$301,009 |
$459,869 |
| Total People Sold |
0 |
3 |
3 |
4 |
| Total Sell Transactions |
0 |
6 |
8 |
21 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Buehler Kevin |
Director |
– • – |
2025-06-25 |
4 |
B |
$4.16 |
$21,116 |
D/D |
5,076 |
28,137 |
2.39 |
- |
|
| Brown Melinda |
Director |
– • – |
2025-06-25 |
4 |
B |
$4.14 |
$6,963 |
D/D |
1,682 |
20,565 |
2.39 |
- |
|
| Brown Melinda |
|
– • – |
2025-05-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,826 |
18,883 |
|
- |
|
| Germano Geno J |
|
– • – |
2025-05-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,826 |
20,883 |
|
- |
|
| Buehler Kevin |
|
– • – |
2025-05-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,826 |
23,061 |
|
- |
|
| Pire Shari Lisa |
|
– • – |
2025-05-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,826 |
14,028 |
|
- |
|
| Frankel Stanley |
|
– • – |
2025-05-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,826 |
14,078 |
|
- |
|
| Brown Melinda |
|
– • – |
2025-03-26 |
4 |
B |
$4.75 |
$8,735 |
D/D |
1,839 |
9,057 |
0.01 |
-9% |
|
| Buehler Kevin |
|
– • – |
2025-03-26 |
4 |
B |
$4.67 |
$21,122 |
D/D |
4,523 |
13,235 |
0.01 |
-9% |
|
| Germano Geno J |
|
– • – |
2025-03-25 |
4 |
B |
$5.30 |
$17,225 |
D/D |
3,250 |
11,057 |
0.01 |
-19% |
|
| Amoroso Michael |
President and CEO |
• • – |
2025-03-24 |
4 |
AS |
$5.56 |
$5,360 |
D/D |
(964) |
109,540 |
|
-24% |
|
| Amoroso Michael |
President and CEO |
• • – |
2025-03-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,417 |
110,504 |
|
- |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2025-03-04 |
4 |
AS |
$4.91 |
$1,336 |
D/D |
(272) |
25,000 |
|
-16% |
|
| Smith J. Jefferson |
Chief Research Officer |
• – – |
2025-03-04 |
4 |
AS |
$4.91 |
$756 |
D/D |
(154) |
87,805 |
|
-16% |
|
| Kelly John Alexander |
Chief Financial Officer |
• – – |
2025-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,702 |
86,256 |
|
- |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2025-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
919 |
25,272 |
|
- |
|
| Smith J. Jefferson |
Chief Research Officer |
• – – |
2025-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
519 |
87,959 |
|
- |
|
| Smith J. Jefferson |
Chief Research Officer |
• – – |
2025-01-22 |
4 |
AS |
$4.79 |
$49,275 |
D/D |
(10,287) |
87,440 |
|
1% |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2025-01-22 |
4 |
AS |
$4.79 |
$42,765 |
D/D |
(8,928) |
24,353 |
|
1% |
|
| Amoroso Michael |
President and CEO |
• • – |
2025-01-21 |
4 |
AS |
$4.67 |
$172,033 |
D/D |
(36,838) |
107,087 |
|
6% |
|
| Smith J. Jefferson |
Chief Research Officer |
• – – |
2025-01-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,168 |
97,727 |
|
- |
|
| Amoroso Michael |
President and CEO |
• • – |
2025-01-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
115,388 |
143,925 |
|
- |
|
| Kelly John Alexander |
Chief Financial Officer |
• – – |
2025-01-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
44,368 |
84,554 |
|
- |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2025-01-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,312 |
33,281 |
|
- |
|
| Germano Geno J |
|
– • – |
2024-12-30 |
4 |
B |
$4.49 |
$16,186 |
D/D |
3,605 |
7,807 |
0.01 |
23% |
|
218 Records found
|
|
Page 1 of 9 |
|
|
0.16 (3.86%) 
